| Description | Clazakizumab, a monoclonal antibody, demonstrates high affinity and specificity towards the interleukin-6 (IL-6) cytokine, potentially inhibiting the cytokine response in COVID-19 caused by SARS-CoV-2. It is also under research for treating psoriatic arthritis (PsA) and renal antibody-mediated rejection [1] [2]. |
| molecular weight | N/A |
| CAS | 1236278-28-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |